RARE Quote, Financials, Valuation and Earnings

Chimerix has a net margin of -80.9% compared to Ultragenyx Pharmaceutical's net margin of -40270.18%. Ultragenyx Pharmaceutical's return on equity of -194.36% beat Chimerix's return on equity of -56.65%.

Ultragenyx Pharmaceutical has a consensus price target of $90.21, signalling upside risk potential of 135.72%. On the other hand Chimerix has an analysts' consensus of $8.54 which suggests that it could grow by 0.24%. Given that Ultragenyx Pharmaceutical has higher upside potential than Chimerix, analysts believe Ultragenyx Pharmaceutical is more attractive than Chimerix.

Ultragenyx Pharmaceutical has a beta of 0.668, which suggesting that the stock is 33.17% less volatile than S&P 500. In comparison Chimerix has a beta of 0.324, suggesting its less volatile than the S&P 500 by 67.586%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Chimerix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Chimerix pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $164.9M, which are larger than Chimerix quarterly revenues of $57K. Ultragenyx Pharmaceutical's net income of -$133.4M is lower than Chimerix's net income of -$23M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Chimerix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 6.14x versus -- for Chimerix. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of -80.9% compared to Ultragenyx Pharmaceutical's net margin of -46.06%. Ultragenyx Pharmaceutical's return on equity of -194.36% beat Ionis Pharmaceuticals's return on equity of -103.27%.

Ultragenyx Pharmaceutical has a consensus price target of $90.21, signalling upside risk potential of 135.72%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $59.42 which suggests that it could grow by 88.69%. Given that Ultragenyx Pharmaceutical has higher upside potential than Ionis Pharmaceuticals, analysts believe Ultragenyx Pharmaceutical is more attractive than Ionis Pharmaceuticals.

Ultragenyx Pharmaceutical has a beta of 0.668, which suggesting that the stock is 33.17% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.279, suggesting its less volatile than the S&P 500 by 72.122%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $164.9M, which are smaller than Ionis Pharmaceuticals quarterly revenues of $226.6M. Ultragenyx Pharmaceutical's net income of -$133.4M is lower than Ionis Pharmaceuticals's net income of -$104.3M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 6.14x versus 6.68x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -80.9% compared to Ultragenyx Pharmaceutical's net margin of 24.22%. Ultragenyx Pharmaceutical's return on equity of -194.36% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Ultragenyx Pharmaceutical has a consensus price target of $90.21, signalling upside risk potential of 135.72%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 44.19%. Given that Ultragenyx Pharmaceutical has higher upside potential than Regeneron Pharmaceuticals, analysts believe Ultragenyx Pharmaceutical is more attractive than Regeneron Pharmaceuticals.

Ultragenyx Pharmaceutical has a beta of 0.668, which suggesting that the stock is 33.17% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.14% to investors and pays a quarterly dividend of $0.88 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $164.9M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Ultragenyx Pharmaceutical's net income of -$133.4M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 16.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 6.14x versus 5.19x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of -80.9% compared to Ultragenyx Pharmaceutical's net margin of -9.24%. Ultragenyx Pharmaceutical's return on equity of -194.36% beat Vanda Pharmaceuticals's return on equity of -3.49%.

Ultragenyx Pharmaceutical has a consensus price target of $90.21, signalling upside risk potential of 135.72%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 165.55%. Given that Vanda Pharmaceuticals has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Vanda Pharmaceuticals is more attractive than Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical has a beta of 0.668, which suggesting that the stock is 33.17% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.079%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $164.9M, which are larger than Vanda Pharmaceuticals quarterly revenues of $53.2M. Ultragenyx Pharmaceutical's net income of -$133.4M is lower than Vanda Pharmaceuticals's net income of -$4.9M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 6.14x versus 1.40x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.